Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar 1stMartian (48.80) Submitted: 12/6/2011 11:26:56 PM : Underperform Start Price: $7.41 PGNX Score: -9.06

Piggy back off Z's analysis.

Featured Broker Partners


Advertisement